State of emergency contraception in the U.S., 2018

Autor: Rafael T. Mikolajczyk, Marci Messerle-Forbes, Tara L. Frenkl, Santhamma B, Meece Fa, Alison Edelman, I.J.M. Duijkers, G. Ahmed, Christine Klipping, J. Jensen, Farulla A, ODonnell A, Sandra M. Cruz, Tekmal Rr, Pollok Ne, Nair H, Giovanni Grandi, Norman D Goldstuck, Klaus Nickisch, Lara J, Stanford Jb, Kelly Cleland, Haeger Ko, Filomena Giulia Sileo, Lamme J, Fayad Gn, Sara McCrimmon, Zhao C, Le Hp, Edelman A, Doris Heger-Mahn, Leo Han, Shaked Z, Padua E, Jon D. Hennebold, Fabio Facchinetti, Tjeerd Korver
Rok vydání: 2018
Předmět:
Zdroj: Contraception and Reproductive Medicine
Contraception and Reproductive Medicine, Vol 3, Iss 1, Pp 1-12 (2018)
ISSN: 2055-7426
Popis: Emergency contraception is indicated in instances of unprotected sexual intercourse, including reproductive coercion, sexual assault, and contraceptive failure. It plays a role in averting unintended pregnancies due to inconsistent use or non-use of contraception. Options for emergency contraception vary by efficacy as well as accessibility within the U.S. This paper provides an overview of levonorgestrel (Plan B One-Step and generic counterparts), ulipristal acetate (sold as ella), and the copper intrauterine device (IUD, sold as ParaGard), including the mechanisms of action, administration, efficacy, drug interactions, safety, side effects, advantages, and drawbacks. It will also review current misconceptions about emergency contraception and access for subpopulations, including adolescents, immigrants, survivors of sexual assault, rural populations, and military/veteran women. This paper will address barriers such as gaps in knowledge, and financial, health systems, and practice barriers. Continuing areas of research, including the impact of body weight on the efficacy of emergency contraceptive pills and potential interactions between ulipristal acetate and ongoing hormonal contraceptives, are also addressed.
Databáze: OpenAIRE